**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** CAMPYLOBACTER IS A LEADING CAUSE OF HUMAN DIARRHEAL DISEASE WORLDWIDE, WITH CHICKEN SERVING AS THE PRIMARY SOURCE. APPROXIMATELY $8 BILLION IS SPENT EVERY YEAR IN THE UNITED STATES FOR THE TREATMENT OF CAMPYLOBACTER INFECTIONS IN HUMANS. CURRENTLY, THERE ARE NO EFFECTIVE STRATEGIES TO CONTROL THE SPREAD OF CAMPYLOBACTER FROM CHICKENS TO HUMANS. MOREOVER, GIVEN THE WIDE MISUSE OF ANTIBIOTICS FOR DISEASE CONTROL AND GROWTH PROMOTION ON FARMS, THE PREVALENCE OF ANTIBIOTIC-RESISTANT CAMPYLOBACTER IS LIKELY TO INCREASE. THEREFORE, IT IS CRITICAL TO DEVELOP ALTERNATIVES TO ANTIBIOTICS TO COMBAT DIARRHEAL DISEASES. WE HAVE SHOWN THAT THE PROBIOTIC E. COLI NISSLE INHIBITS CAMPYLOBACTER GROWTH AND PROMOTES THE GROWTH AND GUT HEALTH OF THE HOST. BUILDING OFF THESE PROMISING RESULTS, WE PROPOSE TO IDENTIFY THE BIOACTIVE MOLECULES THAT ALLOW E. COLI NISSLE TO MEDIATE ITS ACTION AGAINST CAMPYLOBACTER AND EVALUATE THE EFFICACY OF THESE BIOACTIVE MOLECULES IN COMBATTING FOODBORNE ILLNESS. THIS STUDYIS SIGNIFICANT AS IT WILL LAY THE GROUNDWORK FOR DEVELOPING AND VALIDATING NOVEL STRATEGIES THAT EFFECTIVELY CONTROL NOT ONLY ANTIBIOTIC-RESISTANT CAMPYLOBACTER BUT ALSO OTHER FOODBORNE PATHOGENS. AS A RESULT, THIS WORK WILL SIGNIFICANTLY ENHANCE FOOD SAFETY IN THE UNITED STATES.